For patients newly diagnosed with small cell lung cancer (SCLC), the conversation about clinical trials should begin immediately, not after other treatments have failed. This is the key message from Dr. Ashish Saxena, Chief of Thoracic Medical Oncology at Weill Cornell Medicine, who stresses that some trials are only available before treatment starts, while others are testing promising therapies as first-line options. In a disease as aggressive as SCLC, timing is critical.
Historically, SCLC has had limited treatment options, but the landscape is shifting rapidly. “There are a lot of changes going on in the landscape today, more than we've seen for a very long time,” says Dr. Saxena. Emerging treatments include immunotherapy, which harnesses the immune system to attack cancer cells, and antibody-drug conjugates, which deliver chemotherapy directly to cancer cells while sparing healthy tissue. Researchers are also gaining a deeper understanding of the biology of SCLC, which could lead to more personalized treatments. “All of these things should give patients a lot of hope when they are diagnosed with small cell lung cancer,” he adds.
Clinical trials are not just about extending life; they are increasingly focused on improving how patients feel. Beyond measuring tumor shrinkage or time to progression, trials now track patient-reported outcomes such as fatigue, breathing difficulties, pain, and emotional well-being. “The goal is to have meaningful time, not just more time,” Dr. Saxena explains. These outcomes can even provide early signals of whether a treatment is working—a cough may ease, breathing may become easier, or energy may return—often before the next scan.
Patients themselves play a crucial role in their care. Speaking up about side effects and changes in how they feel can help doctors adjust medications or dosages, manage symptoms, and potentially keep patients on treatment longer. In clinical trials, this feedback also helps researchers understand the therapy's impact on daily life, not just what appears on imaging.
Wendy Brooks, who is living with SCLC and is a member of the Lung Cancer Foundation of America’s (LCFA) Voices of Hope Speakers Bureau, finds the pace of change encouraging. “I'm more hopeful today than I have ever been,” she says.
The message for patients is clear: don’t wait to ask about clinical trials. Ask early, ask before treatment begins, and keep asking throughout the treatment journey. That one question—“Is there a clinical trial that might be right for me?”—could open doors to options they didn’t know existed.
To hear the full conversation between Wendy Brooks and Dr. Ashish Saxena on the Hope With Answers podcast and to learn more about small cell lung cancer research, clinical trials, and treatment, visit LCFAmerica.org. The Lung Cancer Foundation of America is dedicated to dramatically improving survival rates and quality of life for people diagnosed with lung cancer through funding innovative research, amplifying patient stories, and raising awareness.
